Mosaic Family Wealth Partners LLC Purchases 30,502 Shares of Pfizer Inc. $PFE

Mosaic Family Wealth Partners LLC increased its position in Pfizer Inc. (NYSE:PFE) by 94.3% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 62,835 shares of the biopharmaceutical company’s stock after acquiring an additional 30,502 shares during the quarter. Mosaic Family Wealth Partners LLC’s holdings in Pfizer were worth $1,513,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Vermillion Wealth Management Inc. increased its position in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 382 shares during the period. Eagle Capital Management LLC grew its stake in shares of Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares during the last quarter. Delta Financial Advisors LLC increased its holdings in Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares during the period. Pines Wealth Management LLC increased its holdings in Pfizer by 4.4% in the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares during the period. Finally, Mount Vernon Associates Inc. MD raised its position in Pfizer by 1.0% during the 1st quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock worth $1,177,000 after purchasing an additional 400 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $28.25 on Thursday. The stock has a market capitalization of $161.00 billion, a price-to-earnings ratio of 37.17 and a beta of 0.34. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The stock’s 50 day moving average price is $25.23 and its two-hundred day moving average price is $26.23. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the business posted $0.78 EPS. Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is 226.32%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 melanoma results for their personalized mRNA cancer-vaccine combination with Keytruda, demonstrating improved recurrence-free survival. Pfizer is not directly involved, but the data lifted sentiment across mRNA and oncology companies and highlighted the potential value of Pfizer’s own cancer-vaccine ambitions. Pfizer Stock Rises Wednesday: What’s Going On?
• Positive Sentiment: Pfizer and Valneva received validation from the European Medicines Agency for their Lyme disease vaccine application, allowing the filing to proceed to full regulatory review after encouraging late-stage efficacy and safety results. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Positive Sentiment: Unusually heavy call-option activity indicated increased speculative interest: investors bought 170,284 call options, roughly 47% above typical daily volume. This is a sentiment signal rather than a change to Pfizer’s fundamentals.
• Positive Sentiment: Pfizer’s potential monthly obesity treatment, berobenatide, could provide entry into the fast-growing GLP-1 market if clinical development and market-share objectives are achieved. Pfizer’s Obesity Push
• Neutral Sentiment: Merck’s increased investment in personalized cancer vaccines raises the competitive bar for Pfizer and BioNTech. The development validates the market opportunity but could make it harder for Pfizer to differentiate its pipeline. Merck Just Raised the Stakes for Pfizer’s Cancer Vaccine Ambitions
• Negative Sentiment: Investors continue to debate Pfizer’s looming patent cliff, which could pressure revenue as key products face loss-of-exclusivity risk. The stock’s relatively low valuation and dividend appeal may partly reflect these concerns. Pfizer: Still Cheap Valuation Meets a Looming Patent Cliff

Wall Street Analyst Weigh In

A number of research firms have commented on PFE. Bank of America reduced their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Guggenheim lowered their price objective on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th. JPMorgan Chase & Co. cut their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Weiss Ratings downgraded shares of Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday. Finally, Wolfe Research restated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.